

Irene Scarf \tilde{A}^2

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5050496/publications.pdf>

Version: 2024-02-01

33
papers

2,221
citations

623734

14
h-index

526287

27
g-index

34
all docs

34
docs citations

34
times ranked

3664
citing authors

#	ARTICLE	IF	CITATIONS
1	Blockade or Deletion of IFN γ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2022, 3, 136-153.	5.0	46
2	CAR T cell killing requires the IFN γ R pathway in solid but not liquid tumours. <i>Nature</i> , 2022, 604, 563-570.	27.8	150
3	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 494-508.e5.	16.8	54
4	Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME). <i>Cancer Research</i> , 2022, 82, 569-569.	0.9	0
5	Single-cell imaging of T cell immunotherapy responses in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	16
6	Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	132
7	CRISPR screen identifies loss of IFN γ R signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors. , 2021, 9, A234-A234.		0
8	Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies. <i>Blood</i> , 2021, 138, 653-653.	1.4	5
9	Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma. <i>Blood</i> , 2021, 138, 258-258.	1.4	3
10	Blocking IFN γ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 +malignancies. <i>Blood</i> , 2021, 138, 1723-1723.	1.4	2
11	Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products. <i>Blood</i> , 2021, 138, 3849-3849.	1.4	3
12	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia. <i>Blood</i> , 2021, 138, 405-405.	1.4	1
13	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. , 2020, 8, e000990.		13
14	Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells. <i>Cancer Cell</i> , 2020, 37, 143-144.	16.8	5
15	Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies. , 2020, 8, A815-A815.		1
16	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. <i>Nature Biotechnology</i> , 2019, 37, 1049-1058.	17.5	347
17	Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. <i>Advanced Science</i> , 2019, 6, 1901829.	11.2	19
18	Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. <i>Nature Communications</i> , 2019, 10, 2087.	12.8	117

#	ARTICLE	IF	CITATIONS
19	CAR-Based Approaches to Cutaneous T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 259.	2.8	15
20	Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. <i>Nature Biotechnology</i> , 2019, 37, 276-282.	17.5	439
21	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Advances</i> , 2019, 3, 3248-3260.	5.2	76
22	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. , 2019, 7, 304.		181
23	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. <i>Clinical Cancer Research</i> , 2019, 25, 7046-7057.	7.0	56
24	Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 4443-4443.	1.4	6
25	Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells. <i>Blood</i> , 2019, 134, 5626-5626.	1.4	1
26	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. <i>Blood</i> , 2018, 132, 1495-1506.	1.4	100
27	Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma. <i>Blood</i> , 2018, 132, 2059-2059.	1.4	5
28	Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. , 2017, 5, 28.		154
29	The RNA-binding protein ESRP1 promotes human colorectal cancer progression. <i>Oncotarget</i> , 2017, 8, 10007-10024.	1.8	57
30	The heterogeneous landscape of ALK negative ALCL. <i>Oncotarget</i> , 2017, 8, 18525-18536.	1.8	28
31	Transposable elements: The enemies within. <i>Experimental Hematology</i> , 2016, 44, 913-916.	0.4	1
32	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016, 127, 221-232.	1.4	97
33	The KrÄppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	7.2	84